In June of 2013, an article by Erika Gebel, Phd, published at Diabetes Forecast said that SGLT2 medications, including Invokana, target the kidneys. While her article was not entirely negative she did recognize even then that there were concerns about SGLT-2 inhibitors:
"There have been reports of serious diabetic ketoacidosis events in a few type 2 cases ...."
As the American Diabetes Association has said, ketoacidosis can lead to death. Accordingly, it was reported as early as 2013 that Invokana could lead to DKA (diabetic ketoacidosis), which can lead to death if not properly and quickly treated.